Market Place
Sourcing Support
Acelyrin Reports Q3 2024 Results & Highlights
13 Nov 2024 //
GLOBENEWSWIRE
Acelyrin to Report Q3 2024 Financials & Updates on Nov 13
06 Nov 2024 //
GLOBENEWSWIRE
Acelyrin Forms Advisory Board Featuring Voices In Thyroid Eye Disease
16 Oct 2024 //
GLOBENEWSWIRE
ACELYRIN Announces Positive Results For Izokibep Trial
19 Sep 2024 //
GLOBENEWSWIRE
Acelyrin Announces Positive Lonigutamab Phase 1/2 Data
10 Sep 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
22 Aug 2024 //
GLOBENEWSWIRE
Acelyrin Loses Izokibep Interest, Lays Off 3rd Of Staff For Tepezza Fight
14 Aug 2024 //
FIERCE BIOTECH
ACELYRIN Reports Positive Phase 3 Data And Q2 2024 Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
ACELYRIN To Report Q2 2024 Results On August 13
06 Aug 2024 //
GLOBENEWSWIRE
ACELYRIN: Izokibep Phase 2b/3 PsA Data At EULAR 2024 Late-Breaker
05 Jun 2024 //
GLOBENEWSWIRE
ACELYRIN Lonigutamab Phase 1/2 Data At ENDO 2024 Late-Breaker
29 May 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. Announces Leadership Transition
09 May 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
09 May 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. Announces Leadership Transition - May 09, 2024
09 May 2024 //
BIOSPACE
ACELRYN Q1 2024 Results & Corporate Update on May 13
29 Apr 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. Reports Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. Announces Positive Ph 1/2 Proof-of-Concept Data for Lonigutamab
20 Mar 2024 //
GLOBENEWSWIRE
Acelyrin`s proof-of-concept TED data cement Amgen challenge
20 Mar 2024 //
FIERCE BIOTECH
ACELYRIN Announces Positive Results from Phase 2b/3 Trial of Izokibep
11 Mar 2024 //
GLOBENEWSWIRE
Acelyrin rebounds with psoriatic arthritis victory
11 Mar 2024 //
FIERCE BIOTECH
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President
15 Feb 2024 //
GLOBENEWSWIRE
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
20 Dec 2023 //
GLOBENEWSWIRE
Fortrea `disputes the accuracy` of Acelyrin`s claims about immunology drug trial
30 Nov 2023 //
ENDPTS
Could a CRO error explain Acelyrin`s shocking phase 3 failure?
28 Nov 2023 //
FIERCE BIOTECH
Acelyrin says CRO Fortrea made errors in trial of lead immunology drug izokibep
27 Nov 2023 //
ENDPTS
ACELYRIN Reports Third Quarter 2023 Financial Results and Recent Highlights
07 Nov 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
06 Nov 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
ACELYRIN Appointed Dr. Shephard Mpofu as Senior Vice President of Development
03 Oct 2023 //
GLOBENEWSWIRE
Aditum launches Celexor with autoimmune drug from Acelyrin partner Inmagene
21 Sep 2023 //
ENDPTS
ACELYRIN Announces Results from Placebo-Controlled Clinical Trial of Izokibep
11 Sep 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Acelyrin Reports Second Quarter 2023 Financial Results And Recent Highlights
14 Aug 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer
18 Jul 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. Reports 1Q 2023 Financial Results and Recent Highlights
15 Jun 2023 //
GLOBENEWSWIRE
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering
09 May 2023 //
PR NEWSWIRE
Acelyrin sets out massive $540M upsized IPO
05 May 2023 //
FIERCE BIOTECH
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering
04 May 2023 //
PR NEWSWIRE
ACELYRIN, INC. Announces Launch of IPO Roadshow
01 May 2023 //
PR NEWSWIRE
Acelyrin eyes IPO boost to $400M haul to take on Lilly, Novartis
14 Apr 2023 //
FIERCE BIOTECH
Acelyrin Announces Magnitude of Clinical Responses with Izokibep
11 Apr 2023 //
PR NEWSWIRE
Henry Gosebruch Joins Acelyrin Board of Directors
29 Mar 2023 //
PR NEWSWIRE
Acelyrin Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks
18 Mar 2023 //
PR NEWSWIRE
ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
05 Jan 2023 //
PR NEWSWIRE
ACELYRIN Furthers Leadership Position Immunology with Acquisition of ValenzaBio
05 Jan 2023 //
BIOSPACE
Former Merck President Dawn Svoronos joins ACELYRIN Board of Directors
13 Dec 2022 //
PRNEWSWIRE
ACELYRIN Announces Ph2 Data for Izokibep in Psoriatic Arthritis That Demonstrate
09 Nov 2022 //
PRNEWSWIRE
ACELYRIN Announces $300 Mil Financing for PIII Development of Izokibep
13 Sep 2022 //
PRNEWSWIRE
Acelyrin brings total raised in 1 year past past $500M mark
13 Sep 2022 //
FIERCEBIOTECH
ACELYRIN Appoints Biotechnology Veteran Gil M. Labrucherie as CFO
12 Jul 2022 //
PRNEWSWIRE
ACELYRIN, Affibody. Inmagene Biopharma Announce Data from PII Trial of Izokibep
03 Jun 2022 //
PRNEWSWIRE
Frontiers Paper Discloses Promising New Insights into CAR T Cell Efficacy
17 Mar 2022 //
PRNEWSWIRE
